| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | See Remarks | President and CEO +1 more
2 companies
Thomas E. Hughes last filed a Form 4 in May 2020, as See Remarks at LRMR. The filings on record cover 2 companies. Thomas E. Hughes's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 12,827 shares of VRDN. The VRDN filings lean toward selling, a net 2,000 shares.
Thomas E. Hughes has 22 Form 4 filings on record from March 2015 to May 2020, across 2 companies: Director at Viridian Therapeutics, Inc.\DE (VRDN), 2017–2020; Larimar Therapeutics (LRMR), 2015–2018.
The 30 reported transactions were 13 option or other derivative awards, 8 option exercises, 5 open-market sales and 3 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $93K and 4 sales worth about $2.4M.
The largest open-market purchase was 10,000 shares of VRDN at an average $4.77 on October 11, 2018, about $48K.
The largest open-market sale was 45,626 shares of LRMR at an average $42.53 on September 18, 2015, about $1.9M.
Shares as reported in the last Form 4 for each company; the most recent is from May 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 11, 2018 | VRDN Viridian Therapeutics, Inc.\de | Director | Buy | 10,000 | $4.77 | $47,697.00 | +353.7% | |
| Jun 28, 2018 | LRMR Larimar Therapeutics, Inc. | See Remarks | Sell | 32,000 | $10.00 | $320,000.00 | -20.4% | |
| Mar 7, 2018 | LRMR Larimar Therapeutics, Inc. | See Remarks | Sell | 5,000 | $10.00 | $50,000.00 | -3.1% | |
| Dec 20, 2017 | VRDN Viridian Therapeutics, Inc.\de | Director | Sell | 12,000 | $8.00 | $96,000.00 | -80.9% | |
| Aug 29, 2016 | LRMR Larimar Therapeutics, Inc. | President and CEO | Buy | 10,000 | $3.00 | $29,987.00 | +18.5% | |
| Jul 22, 2016 | LRMR Larimar Therapeutics, Inc. | President and CEO | Buy | 5,000 | $3.02 | $15,104.00 | +10.2% | |
| Sep 18, 2015 | LRMR Larimar Therapeutics, Inc. | Chief Executive Officer | Sale+OE | 45,626 | $42.53 | $1,940,670.00 | -98.2% |